Citation Impact
Citing Papers
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition
2006 StandoutNobel
The urgent need to recover MHC class I in cancers for effective immunotherapy
2016
Prevention of cervical cancer through papillomavirus vaccination
2004
The cultural mouse
2001 StandoutNobel
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
2015
Inducible Nitric-oxide Synthase and Nitric Oxide Production in Human Fetal Astrocytes and Microglia
1997 StandoutNobel
The p53 proto-oncogene can act as a suppressor of transformation
1989 Standout
Role of Transforming Growth Factor β in Human Disease
2000 Standout
O-GlcNAc-Specific Antibody CTD110.6 Cross-Reacts with N-GlcNAc2-Modified Proteins Induced under Glucose Deprivation
2011
Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo
1991
Expression of MaTu‐MN protein in human tumor cultures and in clinical specimens
1993
Forty years with homologous recombination
2001 StandoutNobel
Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor
2004 StandoutNobel
Human-tumor-derived cell lines contain common and different transforming genes
1981
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
1994 StandoutNature
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
A Universal Live Cell Barcoding-Platform for Multiplexed Human Single Cell Analysis
2018
Genetic Analysis of the Role of the Asparaginyl Hydroxylase Factor Inhibiting Hypoxia-inducible Factor (HIF) in Regulating HIF Transcriptional Target Genes
2004 StandoutNobel
A novel quasi-viral agent, MaTu, is a two-component system
1992
Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in beta cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response.
1995 StandoutNobel
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
2001 StandoutNature
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
1988 Standout
In Vitro Approaches to the Mechanism of Cell-Mediated Immune Reactions
1971
Mouse cytolytic T lymphocytes induced by xenogeneic rat stimulator cells exhibit specificity for H-2 complex alloantigens.
1977 StandoutNobel
Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex
1975 StandoutNatureNobel
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
1983 StandoutNature
Polymyositis and Dermatomyositis
1975 Standout
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
Cell specificity and an effect of ras on human metallothionein gene expression.
1986
Cyclosporine induces cancer progression by a cell-autonomous mechanism
1999 Nature
Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera.
1979 StandoutNobel
Telomerase activity, cell proliferation, and cancer
1998 StandoutNobel
Ectopic Expression of the Serotonin 1c Receptor and the Triggering of Malignant Transformation
1989 StandoutScienceNobel
Experimental elimination and recovery of double minute chromosomes in malignant cell populations
2009
Colony Inhibition of Fibroblasts from Chimeric Dogs Mediated by the Dogs' Own Lymphocytes and Specifically Abrogated by Their Serum
1970 StandoutNobel
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Hodgkin's Disease: Evidence for a Tumor-Associated Antigen
1971
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells
1983 StandoutNatureNobel
The Clonal Evolution of Tumor Cell Populations
1976 StandoutScience
THE MAMMALIAN URINARY BLADDERAN ACCOMMODATING ORGAN
1975
Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present.
1990
Double minutes in human tumor cells
1982
Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice
1974 Science
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
1983 StandoutNatureNobel
Specific suppressor cells in graft–host tolerance of HLA-identical marrow transplantation
1981 StandoutNatureNobel
Amplification and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells
1985 StandoutNatureNobel
Cell-Mediated Cytotoxicity, Allograft Rejection, and Tumor Immunity
1974 Standout
Chromosomes and cancer
2009
Interferon as a mediator of human lymphocyte suppression.
1980
Polymyositis and Dermatomyositis
1975 Standout
Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
1987 Standout
The cancer connection
2002 StandoutNatureNobel
H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;.
1975 StandoutNobel
The pathogenesis of cancer metastasis
1980 StandoutNature
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma.
1983 StandoutNobel
Studies on cellular immunity to human neuroblastoma cells
1970
Growth Factors and Cancer
1991 StandoutScience
The Molecular Genetics of Cancer
1987 StandoutScienceNobel
Studies on cellular immunity and its serum‐mediated inhibition in moloney‐virus‐induced mouse sarcomas
1969
Cellular Immunity Against Tumor Antigens
1969
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes
1982 Nature
The chromosomal aberraation of double-minutes in three gliomas
1970
Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.
1991
The Involvement of Activated Specific Suppressor T Cells in Maintenance of Transplantation Tolerance
1979
H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus.
1975 StandoutNobel
Effect of Interferon-α1 from E. coli on Some Cell Functions
1980 StandoutScienceNobel
Radioimmunoassay of the cellular protein p53 in mouse and human cell lines.
1982
Induction and Evasion of Host Defenses by Type 1-Piliated Uropathogenic Escherichia coli
1998 StandoutScience
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
1985 Standout
Oncogenes in solid human tumours
1982 Nature
Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells
1982 Nature
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Passive Immunotherapy of Cancer in Animals and Man
1977
The novel metallothionein genes of Caenorhabditis elegans. Structural organization and inducible, cell-specific expression.
1993 StandoutNobel
Detection of Telomerase Activity in Exfoliated Cells in Urine From Patients With Bladder Cancer
1997
A BIOLOGICAL ROLE FOR THE MAJOR HISTOCOMPATIBILITY ANTIGENS
1975 StandoutNobel
Purification of Hodgkin's Disease Tumor-Associated Antigens
1973 StandoutNobel
Immunodepression and Malignancy
1976
Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene
1983 Nature
Biological significance of alloreactivity: T cells stimulated by Sendai virus-coated syngeneic cells specifically lyse allogeneic target cells.
1978 StandoutNobel
SERUM-MEDIATED PROTECTION OF NEOPLASTIC CELLS FROM INHIBITION BY LYMPHOCYTES IMMUNE TO THEIR TUMOR-SPECIFIC ANTIGENS
1969
Glyco-seek: Ultrasensitive Detection of Protein-Specific Glycosylation by Proximity Ligation Polymerase Chain Reaction
2016 StandoutNobel
Biologic and antigenic similarity of virus-induced migration inhibition factor to conventional, lymphocyte-derived migration inhibition factor.
1975 StandoutNobel
Works of J Bubeník being referenced
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
2011
Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice
1988
Minute chromatin bodies in two mouse tumours induced in vivo by Rous sarcoma virus.
1968
Cellular and humoral immune responses to human urinary bladder carcinomas
1970
MHC class I down-regulation: tumour escape from immune surveillance? (Review)
2004
The dual effect of antibodies against sex-linked histocompatibility antigen.
1966
Immunotheraphy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2
1990
Participation of 7S and 19S antibodies in enhancement and resistance to methylcholanthrene-induced tumours.
1965
Inhibitory effect of immune serum on carcinogenesis in mice neonatally infected with murine sarcoma virus (Harvey).
1968
A Transmissible Antigen Detected in Two Cell Lines Derived from Human Tumours
1974
Immune response to urinary bladder tumours in man
1970
Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.
2001
ATTEMPTS TO COMPARE THE EFFECTIVENESS OF BLOCKING FACTORS AND ENHANCING ANTIBODIES IN VIVO AND IN VITRO
1975
Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen
1973
Factors influencing the induction of enhancement and resistance to methylcholanthrene-induced tumours in a syngenic system.
1965
Enhancing Effect on Tumour Growth of Humoral Antibodies against Tumour Specific Transplantation Antigens in Tumours induced by Murine Sarcoma Virus (Harvey)
1968 Nature